Solid Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Solid Biosciences sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Solid Biosciences: 6 sponsored US clinical trials, 4 recruiting.
Solid Biosciences sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Duchenne Muscular Dystrophy, with 2 trials.
Upper-quartile sponsor footprint
Solid Biosciences sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
NCT07148089
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
NCT07180355
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
NCT07160634
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
NCT06138639
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
NCT03368742
Evaluation of Home Based Assessments on Participants With DMD
NCT05657938
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Solid Biosciences pipeline
4 recruiting of 6 indexed (67% open); 1 completed (17%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Duchenne Muscular Dystrophy (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Solid Biosciences: open-pipeline peers nationwide
Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Solid Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
- Alexander B Olawaiye, MD · 67% recruiting · 3 trials
Related
What to do with this Solid Biosciences page
6 registered trials is a research-attention snapshot, not an endorsement of Solid Biosciences or any single study.
- 4 of Solid Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Duchenne Muscular Dystrophy is the condition Solid Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Duchenne Muscular Dystrophy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Solid Biosciences pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.